Harvard Health Letter

Changing the cardiovascular prevention game

Results of the JUPITER trial showed that people with low LDL cholesterol but with a high C-reactive protein level who took the statin rosuvastatin had a dramatic decrease in risk of serious cardiovascular events.
To continue reading this article, you must login.
  • Research health conditions
  • Check your symptoms
  • Prepare for a doctor's visit or test
  • Find the best treatments and procedures for you
  • Explore options for better nutrition and exercise
Learn more about the many benefits and features of joining Harvard Health Online »